Search results
Showing results for
The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.
Daniel O'Connor
BSc AFHEA MSc DPhil (OXON) Daniel O'Connor - Associate Professor | Head of Bioinformatics
Robert Shaw
MA (Cantab), MSci (Cantab), MBBS (Imp), MRCP (UK), DPhil (Oxon) Robert Shaw - Senior Vaccine Clinical Trials Physician
Yama G.Farooq
BCA Computer Application , MSc in Information Technology and Software Engineering Yama G.Farooq - Programming and Data Management Director
Stephane Paulus
MD, DTM&H, FRCPCH Stephane Paulus - Consultant in Paediatric Infectious Diseases
Sir Andrew Pollard
BSc MBBS PhD (Lond), DIC, MRCP (UK), FHEA, FRCPCH, MA, FMedSci, FRS Sir Andrew Pollard - Ashall Professor of Infection & Immunity
Emma Plested
Emma Plested - Programme and Regulatory Affairs Director (UK)
Parvinder Aley
OBE, PhD Parvinder Aley - Director of Global Operations (OVG)

